Treatment for mood and anxiety disorders: quetiapine and aripiprazole (Q35176180)

6 August 2017

1 reference

title

Treatment for mood and anxiety disorders: quetiapine and aripiprazole (English)

1 reference

6 August 2017

Martha Sajatovic

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Current Psychiatry Reports

6 August 2017

published in

1 reference

6 August 2017

volume

5

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

320-326

1 reference

Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis

6 August 2017

cites work

1 reference

12 December 2020

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

1 reference

12 December 2020

Quetiapine alone and added to a mood stabilizer for serious mood disorders

1 reference

12 December 2020

Aripiprazole: profile on efficacy and safety

1 reference

12 December 2020

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

1 reference

12 December 2020

Clozapine, obsessive symptoms, and serotonergic mechanisms

1 reference

12 December 2020

Clinical use of quetiapine in disease states other than schizophrenia.

1 reference

12 December 2020

The use of quetiapine for treatment-resistant bipolar disorder: a case series

1 reference

12 December 2020

1 reference

12 December 2020

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study

1 reference

12 December 2020

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

12 December 2020

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1 reference

12 December 2020

Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.

1 reference

12 December 2020

Broad therapeutic uses of atypical antipsychotic medications

1 reference

12 December 2020

Risperidone and obsessive-compulsive symptoms

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

1 reference

12 December 2020

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

1 reference

12 December 2020

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

12 December 2020

Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia

1 reference

12 December 2020

Risperidone in the treatment of acute stress disorder in physically traumatized in‐patients

1 reference

12 December 2020

Partial dopamine agonists in the treatment of psychosis

1 reference

12 December 2020

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

1 reference

12 December 2020

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

12 December 2020

The pharmacology and toxicology of atypical antipsychotic agents

1 reference

12 December 2020

Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS

1 reference

12 December 2020

Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing.

1 reference

12 December 2020

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

12 December 2020

Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania

1 reference

12 December 2020

10.1007/S11920-003-0062-9

Identifiers

DOI

1 reference

release_pbwnzn2jivffrk3ohghwo52swu

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pbwnzn2jivffrk3ohghwo52swu

24 November 2022

mapped directly with Wikidata item

1 reference